Open Access Articles- Top Results for Neuropeptide Y receptor

Neuropeptide Y receptor

neuropeptide Y receptor Y1
Symbol NPY1R
Alt. symbols NPYR
Entrez 4886
HUGO 7956
OMIM 162641
RefSeq NM_000909
UniProt P25929
Other data
Locus Chr. 4 q31.3-q32
neuropeptide Y receptor Y2
Symbol NPY2R
Entrez 4887
HUGO 7957
OMIM 162642
RefSeq NM_000910
UniProt P49146
Other data
Locus Chr. 4 q31
pancreatic polypeptide receptor 1
Symbol PPYR1
Alt. symbols NPY4R, Y4, PP1
Entrez 5540
HUGO 9329
OMIM 601790
RefSeq NM_005972
UniProt P50391
Other data
Locus Chr. 10 q11.2
neuropeptide Y receptor Y5
Symbol NPY5R
Entrez 4889
HUGO 7958
OMIM 602001
RefSeq NM_006174
UniProt Q15761
Other data
Locus Chr. 4 q31-q32

Neuropeptide Y receptors are a class of G-protein coupled receptors which are activated by the closely related peptide hormones neuropeptide Y, peptide YY and pancreatic polypeptide.[1] These receptors are involved in the control of a diverse set of behavioral processes including appetite, circadian rhythm, and anxiety.[2][3][4][5][6][7]

Activated neuropeptide receptors release the Gi subunit from the heterotrimeric G protein complex. The Gi subunit in turn inhibits the production of the second messenger cAMP from ATP.


There are five known mammalian neuropeptide Y receptors designated Y1 through Y5.[8] Four neuropeptide Y receptors each encoded by a different gene have been identified in humans, all of which may represent therapeutic targets for obesity and other disorders.[9][10][11]



  1. ^ Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (March 1998). "XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors". Pharmacol. Rev. 50 (1): 143–50. PMID 9549761. 
  2. ^ Heilig M (August 2004). "The NPY system in stress, anxiety and depression". Neuropeptides 38 (4): 213–24. PMID 15337373. doi:10.1016/j.npep.2004.05.002. 
  3. ^ Harro J (October 2006). "CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies". Amino Acids 31 (3): 215–30. PMID 16738800. doi:10.1007/s00726-006-0334-x. 
  4. ^ Eaton K, Sallee FR, Sah R (2007). "Relevance of neuropeptide Y (NPY) in psychiatry". Current Topics in Medicinal Chemistry 7 (17): 1645–59. PMID 17979774. doi:10.2174/156802607782341037. 
  5. ^ Xapelli S, Agasse F, Ferreira R, Silva AP, Malva JO (November 2006). "Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide". Recent Patents on CNS Drug Discovery 1 (3): 315–24. PMID 18221213. doi:10.2174/157488906778773689. 
  6. ^ Vona-Davis LC, McFadden DW (2007). "NPY family of hormones: clinical relevance and potential use in gastrointestinal disease". Current Topics in Medicinal Chemistry 7 (17): 1710–20. PMID 17979780. doi:10.2174/156802607782340966. 
  7. ^ Lindner D, Stichel J, Beck-Sickinger AG (September 2008). "Molecular recognition of the NPY hormone family by their receptors". Nutrition (Burbank, Los Angeles County, Calif.) 24 (9): 907–17. PMID 18725086. doi:10.1016/j.nut.2008.06.025. 
  8. ^ Larhammar D, Salaneck E (2004). "Molecular evolution of NPY receptor subtypes". Neuropeptides 38 (4): 141–51. PMID 15337367. doi:10.1016/j.npep.2004.06.002. 
  9. ^ Kamiji MM, Inui A (October 2007). "Neuropeptide y receptor selective ligands in the treatment of obesity". Endocrine Reviews 28 (6): 664–84. PMID 17785427. doi:10.1210/er.2007-0003. 
  10. ^ MacNeil DJ (2007). "NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs". Current Topics in Medicinal Chemistry 7 (17): 1721–33. PMID 17979781. doi:10.2174/156802607782341028. 
  11. ^ Kamiji MM, Inui A (2007). "NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?". Current Topics in Medicinal Chemistry 7 (17): 1734–42. PMID 17979782. doi:10.2174/156802607782340957. 

External links

Lua error in package.lua at line 80: module 'Module:Buffer' not found.